These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23871271)

  • 1. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
    Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA;
    Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
    Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
    Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
    Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
    Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD
    Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
    Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
    Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
    Mirkin S; Komm BS; Pan K; Chines AA
    Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.
    Christiansen C; Chesnut CH; Adachi JD; Brown JP; Fernandes CE; Kung AW; Palacios S; Levine AB; Chines AA; Constantine GD
    BMC Musculoskelet Disord; 2010 Jun; 11():130. PubMed ID: 20569451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.
    de Villiers TJ; Chines AA; Palacios S; Lips P; Sawicki AZ; Levine AB; Codreanu C; Kelepouris N; Brown JP
    Osteoporos Int; 2011 Feb; 22(2):567-76. PubMed ID: 20535606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bazedoxifene in postmenopausal Latino women with osteoporosis.
    Bueno JAH; Arias L; Yu CR; Williams R; Komm BS
    Menopause; 2017 Sep; 24(9):1033-1039. PubMed ID: 28837504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.
    Pickar JH; Yeh IT; Bachmann G; Speroff L
    Fertil Steril; 2009 Sep; 92(3):1018-1024. PubMed ID: 19635613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status.
    Adami S; Palacios S; Rizzoli R; Levine AB; Sutradhar S; Chines AA
    Climacteric; 2014 Jun; 17(3):273-84. PubMed ID: 23937421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Palacios S
    Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene.
    Reginster JY; Ferrari S; Hadji P
    Curr Med Res Opin; 2014 Jun; 30(6):1165-76. PubMed ID: 24495098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
    Palacios S; Silverman SL; de Villiers TJ; Levine AB; Goemaere S; Brown JP; De Cicco Nardone F; Williams R; Hines TL; Mirkin S; Chines AA;
    Menopause; 2015 Aug; 22(8):806-13. PubMed ID: 25668306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.
    Ohta H; Solanki J
    Osteoporos Int; 2015 Mar; 26(3):849-63. PubMed ID: 25448837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
    Hadji P
    Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424.
    Drugs R D; 2008; 9(3):191-6. PubMed ID: 18457472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study.
    Pickar JH; Lavenberg J; Pan K; Komm BS
    Menopause; 2018 Mar; 25(3):273-285. PubMed ID: 29088019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
    Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
    Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis.
    Beck TJ; Fuerst T; Gaither KW; Sutradhar S; Levine AB; Hines T; Yu CR; Williams R; Mirkin S; Chines AA
    Bone; 2015 Aug; 77():115-9. PubMed ID: 25917574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.